Patients with a rare blood cancer that has relapsed or become resistant to treatment have shown a high response rate to a ...

In the largest prospective study to date examining the use of chimeric antigen receptor (CAR)-T therapy in a community ...

The Leukemia and Lymphoma Society is once again hosting Light The Night to bring light to the darkness of cancer. Last year, ...

an uncommon type of non-Hodgkin lymphoma (blood cancer), in 2022. Sam has been undergoing chemotherapy since March 2023, and has spoken out about how aggressive treatment is. He previously had ...

a feature that represents an important hallmark of cancer. 16 We observed two peaks of CAR T-cell expansion. The first peak was clinically expected and eradicated the B-cell lymphoma, whereas the ...

The City of Rockville will hold the Leukemia & Lymphoma Society’s Light The Night event on Saturday, Oct. 5. Light The Night ...

An event aimed at spreading light and hope for patients and families dealing with the impacts of blood cancer returns Thursday.The Leukemia & Lymphoma Society's "Light the Night" event will return ...

Epkinly showed an overall response rate of 82% with 62.5% of patients achieving complete response. 65% of patients had grade 1-2 cytokine release syndrome (CRS), though severe cases (grade 3) were ...

Integrated DNA Technologies (IDT) has introduced the Archer VARIANTPlex Lymphoma panel, a new tool for next-generation sequencing (NGS) to add to its ...

Acalabrutinib, a Bruton tyrosine kinase inhibitor, is currently approved under the brand name Calquence ® for MCL in patients who have received at least 1 prior therapy. It is also indicated for the ...

An event aimed at spreading light and hope for patients and families dealing with the impacts of blood cancer is set to return this week.On Thursday, the Leukemia & Lymphoma Society's "Light the ...

Red, yellow and white lanterns decorated Milwaukee's lakefront Thursday night, Sept. 26 The Leukemia & Lymphoma Society's annual Light the Night is seeing big attendance numbers.I ...